Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks

SWORD studies demonstrate long-term durable efficacy and tolerability of Juluca, the first complete 2-drug regimen, for the treatment of virologically suppressed adults with HIV

Published
05 April 2019
From
ViiV press release
Early ART in HIV Possible Key to Dolutegravir Monotherapy Success

Several randomized controlled trials have shown dolutegravir monotherapy to be inferior to cART. These dolutegravir monotherapy trials, however, have been conducted in patients initiating cART during chronic rather than primary HIV infection. Since patients who start cART during the early phase of HIV infection show a reduced HIV reservoir and low viral diversity, the researchers evaluated whether these properties would allow for sustained virologic suppression after a switch to dolutegravir monotherapy.

Published
15 February 2019
From
Infectious Disease Advisor
FDA To Consider Pifeltro, Delstrigo as HIV Switch-On Therapies

The FDA will decide this year whether the once-daily Merck therapies can be marketed as a switch-on drug for patients with suppressed HIV-1.

Published
23 January 2019
From
MD Magazine
Dolutegravir Monotherapy for HIV No Longer Recommended

Dolutegravir monotherapy should no longer be used as HIV maintenance therapy, according to Bart J.A. Rijnders, MD, PhD, and Casper Rokx, MD, PhD, both from Erasmus Medical Center, Rotterdam, the Netherlands.

Published
09 January 2019
From
Contagion Live
Dual HIV Regimen Equaled Triple Even After Treatment Failure

A "dual" combination of raltegravir (Isentress) plus boosted protease inhibitor was comparable to triple combination regimens with raltegravir for HIV in treatment-experienced patients, including those with previous treatment failure, in a retrospective study with real-world cohort.

Published
26 November 2018
From
MD Magazine
Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens

The study met its primary endpoint of non-inferior efficacy as measured by the proportion of participants who switched to DELSTRIGO and had plasma HIV-1 RNA levels <50 copies/mL at Week 48 compared to the proportion of participants who continued on their baseline regimen and had HIV-1 RNA levels <50 copies/mL at Week 24.

Published
05 October 2018
From
Merck press release
Janssen Reports Switching to SYMTUZA™ Results in Maintained High Virologic Suppression and No Resistance Development up to 96-Weeks in Virologically Suppressed Adults with HIV-1

Results from the pivotal Phase 3 EMERALD study demonstrate that in adults with HIV-1 who are virologically suppressed, switching to SYMTUZA™ resulted in maintained high virologic suppression (91%, 692/763) and low virologic failure (1%, 9/763) at week 96 (per FDA-Snapshot); low cumulative virologic rebound (3.1%, 24/763); and no resistance development, up to 96-weeks.

Published
05 October 2018
From
Janssen press release
What you need to know about HIV two-drug regimens

Integrase inhibitors—potent antiretrovirals that quickly and powerfully suppress HIV—have allowed HIV researchers and clinicians to explore dosing regimens that involve fewer than three or four drugs. Proponents of dual therapy say that effective regimens involving fewer drugs will lower costs, decrease pill burden and reduce the potential for drug-drug interactions and side effects. But is it that simple?

Published
28 August 2018
From
BETA blog
Meta-analysis of dolutegravir in naive, experienced and switch studies

A meta-analysis of 7340 participants in 13 randomised trials found efficacy and safety benefits for starting dolutegravir compared with other antiretrovirals in both naive and experienced participants. In the four switch studies in participants with undetectable viral load on their current ART, however, changing to dolutegravir was associated with more adverse events and discontinuations.

Published
30 April 2018
From
HIV i-Base
HIV Regimen Switch May Contribute to Weight Gain

According to results of a study presented at IDWeek 2017, an increase in body weight is common in HIV patients who are switched from efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) to an integrase strand transfer inhibitor.

Published
09 October 2017
From
Monthly Prescribing Reference
← First12345...6Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.